Celgene Announces Positive Recommendation By Scottish Medicines Consortium (SMC) For ABRAXANE (Nab-Paclitaxel) In Combination With Gemcitabine1 For Patients With Metastatic Pancreatic Cancer

2015-02-10

抗体

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles; nab-paclitaxel), in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the Scottish Medicines Consortium (SMC) within the National Health Service Scotland.1 Help employers find you! Check out all the jobs and post your resume.

机构